Compare · LQDA vs TVTX
LQDA vs TVTX
Side-by-side comparison of Liquidia Corporation (LQDA) and Travere Therapeutics Inc. (TVTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LQDA and TVTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- TVTX is the larger of the two at $4.98B, about 1.6x LQDA ($3.11B).
- LQDA has been more active in the news (20 items in the past 4 weeks vs 2 for TVTX).
- TVTX has more recent analyst coverage (25 ratings vs 21 for LQDA).
- Company
- Liquidia Corporation
- Travere Therapeutics Inc.
- Price
- -
- -
- Market cap
- $3.11B
- $4.98B
- 1M return
- -49.83%
- -
- 1Y return
- +40.47%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 20
- 2
- Recent ratings
- 21
- 25
Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Travere Therapeutics Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Latest LQDA
- Liquidia Technologies upgraded by BTIG Research with a new price target
- SEC Form 8-K filed by Liquidia Corporation
- SEC Form 4 filed by Liquidia Corporation
- SEC Form 4 filed by Liquidia Corporation
- SEC Form 4 filed by Liquidia Corporation
- SEC Form 4 filed by Liquidia Corporation
- SEC Form 4 filed by Liquidia Corporation
- SEC Form 4 filed by Liquidia Corporation
- SEC Form 4 filed by Liquidia Corporation
- SEC Form 4 filed by Liquidia Corporation
Latest TVTX
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
- Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
- Travere Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Travere Therapeutics Announces Planned Chief Executive Officer Transition
- Chief Research Officer Rote William E. exercised 191,500 shares at a strike of $21.40 and sold $13,135,397 worth of shares (209,048 units at $62.83) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 98,197 units (SEC Form 4)
- EVP, CHIEF COMMERCIAL OFFICER Heerma Peter exercised 258,189 shares at a strike of $15.69 and sold $17,857,830 worth of shares (283,189 units at $63.06) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 117,066 units (SEC Form 4)
- EVP, Head of R&D & CMO Inrig Jula exercised 32,395 shares at a strike of $8.93 and sold $2,785,021 worth of shares (44,674 units at $62.34) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 100,491 units (SEC Form 4)
- Chief Legal Officer and GC Reed Elizabeth E exercised 37,500 shares at a strike of $15.46 and sold $2,337,695 worth of shares (37,500 units at $62.34) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Dube Eric M exercised 400,000 shares at a strike of $23.34 and sold $25,390,729 worth of shares (400,000 units at $63.48) as part of a pre-agreed trading plan (SEC Form 4)